19:52 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver fibrosis Mouse studies suggest inhibiting CELF1 could help treat liver fibrosis. In patient liver tissue samples, CELF1 mRNA expression was higher than in normal liver samples. In a mouse model of bile duct...
07:00 , Mar 14, 2016 |  BioCentury  |  Emerging Company Profile

AMO's CNS ammunition

AMO Pharma Ltd. is in-licensing therapies for rare genetic diseases with no treatment options, starting with two potentially disease-modifying candidates for fragile X syndrome and myotonic dystrophy type 1. The company's first candidate is AMO-01...
08:00 , Dec 3, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiomyopathy associated with muscular dystrophy CUG triplet repeat, RNA binding protein 1 (CUGBP1); protein kinase C (PKC) Studies in mice suggest that inhibiting PKC...